tm logo
Trademark Search
RECOMBUMIN

View On IC.GC.CA

RECOMBUMIN
APPROVED

on 03 Dec 2024

Last Applicant/ Owned by

Albumedix Ltd

HQ, Mabel StreetNottingham NG2 3ED

GB

Serial Number

2199373 filed on 26th May 2022

Correspondent Address

1100-150 York StreetToronto

ONTARIO

CA

M5H3S5

RECOMBUMIN

Trademark usage description

chemicals used in industry, science and for use in the manufacture of pharmaceuticals, namely, active chemical ingredients for use in the manufacture Read More

Classification Information

Class [001]
Chemicals used in industry, science and for use in the manufacture of pharmaceuticals, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, chemical preparations for use in the manufacture of pharmaceuticals, chemical substances for extending the half-life of a protein drug while maintaining its activity, chemical substances for extending the half-life of drugs, chemical substances for use in cell cultures for scientific and research use; chemical reagents for use in genetic research; diagnostic reagents and excipients for medical-scientific research use and for in vitro use in biochemistry, clinical chemistry and microbiology; chemical additives for use in the manufacture of pharmaceuticals; proteins for industrial purposes, namely for use in the manufacture of pharmaceuticals; recombinant human albumin in the nature of excipients for use as a stabilizer for use in the manufacture of cell culture media, for cell and tissue storage and preservation and for the manufacture of diagnostic imaging agents, namely, albumin microspheres and radiolabeled albumin aggregates; cell culture reagents for scientific and research use, laboratory use and for non-medical purposes and chemical preservation reagents for scientific and research use; albumin for use in the manufacture of pharmaceuticals, vaccines, cellular therapies, regenerative medicines and gene therapies; protein in raw material form for the manufacture of pharmaceuticals, cell culture reagents and cell culture media.

Classification kind code

10

Class [005]
Pharmaceuticals for the treatment and prophylaxis of viral diseases, namely colds and flu, COVID-19, bacterial diseases, namely strep throat, tuberculosis, meningococcal, fungal infections, namely, candida, metabolic diseases, namely, diabetes, gout, arthritis, anemia, endocrine diseases, namely, glucagonoma, musculoskeletal diseases, namely, osteoarthritis, rheumatoid arthritis, cardiovascular, cardiopulmonary, genitourinary, namely, urological diseases and disorders, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurodegenerative, neuromuscular diseases, namely, Parkinson's disease, multiple sclerosis, central nervous system, namely, epilepsy, gastrointestinal, hormonal, dermatological diseases, namely, dermatitis, psychiatric diseases and disorders, namely, mood disorders, schizophrenia, autoimmune, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; pharmaceutical products and substances for the treatment and prophylaxis of viral diseases, namely colds and flu, COVID-19, bacterial diseases, namely strep throat, tuberculosis, meningococcal, fungal infections, namely, candida, metabolic diseases, namely, diabetes, gout, arthritis, anemia, endocrine diseases, namely, glucagonoma, musculoskeletal diseases, namely, osteoarthritis, rheumatoid arthritis, cardiovascular, cardiopulmonary, genitourinary, namely, urological diseases and disorders, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurodegenerative, neuromuscular diseases, namely, Parkinson's disease, multiple sclerosis, central nervous system, namely, epilepsy, gastrointestinal, hormonal, dermatological diseases, namely, dermatitis, psychiatric diseases and disorders, namely, mood disorders, schizophrenia, autoimmune, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; albumin, chemical preparations, synthetic peptides, protein supplements, monoclonal, polyclonal, immunological, native and recombinant antibodies, cells, viruses, live viruses, live- attenuated viruses, attenuated viruses, and virus-like particles and viral vectors, vaccines, bone growth media, immune modulators, monoclonal antibodies, biological tissue and tissue cultures, recombinant proteins, nucleic acid sequences, blood plasma, blood components, all being for pharmaceutical use for the treatment and prophylaxis of viral diseases, namely colds and flu, COVID-19, bacterial diseases, namely strep throat, tuberculosis, meningococcal, fungal infections, namely, candida, metabolic diseases, namely, diabetes, gout, arthritis, anemia, endocrine diseases, namely, glucagonoma, musculoskeletal diseases, namely, osteoarthritis, rheumatoid arthritis, cardiovascular, cardiopulmonary, genitourinary, namely, urological diseases and disorders, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurodegenerative, neuromuscular diseases, namely, Parkinson's disease, multiple sclerosis, central nervous system, namely, epilepsy, gastrointestinal, hormonal, dermatological diseases, namely, dermatitis, psychiatric diseases and disorders, namely, mood disorders, schizophrenia, autoimmune, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; recombinant albumin for use as a reagent for medical use, namely, in-vitro fertilization, tissue sealant, tissue and cell cryopreservation, and blood detoxification; diagnostic reagents for medical use; protein supplements for pharmaceutical purposes for the treatment or prophylaxis of viral diseases, namely colds and flu, COVID-19, bacterial diseases, namely strep throat, tuberculosis, meningococcal, fungal infections, namely, candida, metabolic diseases, namely, diabetes, gout, arthritis, anemia, endocrine diseases, namely, glucagonoma, musculoskeletal diseases, namely, osteoarthritis, rheumatoid arthritis, cardiovascular, cardiopulmonary, genitourinary, namely, urological diseases and disorders, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurodegenerative, neuromuscular diseases, namely, Parkinson's disease, multiple sclerosis, central nervous system, namely, epilepsy, gastrointestinal, hormonal, dermatological diseases, namely, dermatitis, psychiatric diseases and disorders, namely, mood disorders, schizophrenia, autoimmune, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; albuminous preparations for medical and veterinary purposes, namely, for the treatment or prophylaxis of viral diseases, namely colds and flu, COVID-19, bacterial diseases, namely strep throat, tuberculosis, meningococcal, fungal infections, namely, candida, metabolic diseases, namely, diabetes, gout, arthritis, anemia, endocrine diseases, namely, glucagonoma, musculoskeletal diseases, namely, osteoarthritis, rheumatoid arthritis, cardiovascular, cardiopulmonary, genitourinary, namely, urological diseases and disorders, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurodegenerative, neuromuscular diseases, namely, Parkinson's disease, multiple sclerosis, central nervous system, namely, epilepsy, gastrointestinal, hormonal, dermatological diseases, namely, dermatitis, psychiatric diseases and disorders, namely, mood disorders, schizophrenia, autoimmune, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; recombinant albumin for biological therapeutic purposes, namely for use in gene therapy, cell therapy and in vitro fertilization.

Classification kind code

10

Mark Details

Serial Number

2199373

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 31st Oct 2023		Search Recorded
Submitted for opposition 256
on 22nd May 2023		Notification of Possible Opposition Sent
Submitted for opposition 67
on 07th Oct 2022		Agent Name Changed
Submitted for opposition 48
on 04th Aug 2022		Agent Changed
Submitted for opposition 257
on 21st Jul 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 20th Jul 2022		Created
Submitted for opposition 31
on 20th Jul 2022		Formalized
Submitted for opposition 30
on 26th May 2022		Filed
Submitted for opposition 238
on 07th Feb 2022		IR Renewed
Submitted for opposition 228
on 07th Feb 2012		International Registration